Valuation: Gilead Sciences, Inc.

Market Cap 167B 859B 146B 135B 125B 237B 15,980B 241B 1,617B 634B 7,847B 628B 615B 27,182B P/E 2026 *
-47.8x
P/E 2027 * 17.5x
Enterprise Value 177B 907B 155B 143B 132B 251B 16,883B 255B 1,709B 670B 8,291B 664B 650B 28,718B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 5.17x
Free-Float
99.88%
Yield 2026 *
2.41%
Yield 2027 * 2.49%
1 day-1.13%
1 week+1.48%
Current month+5.83%
1 month+6.23%
3 months-1.43%
6 months+5.62%
Current year+0.30%
1 week 331.89
Extreme 331.89
349.2
1 month 312.48
Extreme 312.48
349.2
Current year 312.48
Extreme 312.48
396.35
1 year 293.85
Extreme 293.85
396.35
3 years 163.57
Extreme 163.57
396.35
5 years 132.24
Extreme 132.24
396.35
10 years 102.29
Extreme 102.29
396.35
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 71 2020-10-16
Director/Board Member 73 2017-12-31
Director/Board Member 67 2024-01-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%+1.48% - - 169B
+0.09%+0.25%+54.65%+169.19% 1,084B
-1.63%-1.50%+65.79%+62.70% 634B
-1.12%-4.27%+31.10%+84.44% 447B
+0.18%+2.04%+30.19%+26.51% 330B
-6.22%-3.61%+29.15%+32.09% 295B
-1.27%-0.56%+27.21%+46.39% 285B
-0.93%-1.19%-28.85%-40.38% 218B
-1.19%-2.81%+22.63%+66.30% 199B
+0.83%-0.29%-5.13%-31.75% 137B
Average -1.13%+1.21%+25.19%+46.16% 403.15B
Weighted average by Cap. -0.87%+1.91%+38.22%+80.57%

Financials

2026 *2027 *
Net sales 30.47B 156B 26.66B 24.58B 22.74B 43.17B 2,908B 43.89B 294B 115B 1,428B 114B 112B 4,947B 32.38B 166B 28.32B 26.12B 24.17B 45.87B 3,090B 46.64B 313B 123B 1,518B 122B 119B 5,257B
Net income -3.37B -17.3B -2.95B -2.72B -2.52B -4.78B -322B -4.86B -32.58B -12.77B -158B -12.66B -12.39B -548B 9.55B 48.97B 8.35B 7.7B 7.13B 13.53B 911B 13.75B 92.25B 36.16B 448B 35.85B 35.07B 1,550B
Net Debt 9.46B 48.52B 8.28B 7.63B 7.06B 13.4B 903B 13.63B 91.39B 35.83B 443B 35.51B 34.75B 1,536B -96.43M -495M -84.36M -77.79M -71.98M -137M -9.2B -139M -932M -365M -4.52B -362M -354M -15.66B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-09 R$345.02 -1.13% 918
26-07-08 R$348.95 +0.39% 1,850
26-07-07 R$347.60 +4.55% 703
26-07-06 R$332.47 -2.99% 303
26-07-03 R$342.73 +0.80% 6
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.84USD
Average target price
158.30USD
Spread / Average Target
+17.40%

Quarterly revenue - Rate of surprise